Status: Recruiting
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Participants needed: 115
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Beijing HospitalUpdated: May 2, 2025Locations: 16
Eligibility criteria
Age 18 to 70 years (inclusive) at enrollment, regardless of gender. [+6]
Patients with type 1 diabetes or other types of diabetes. [+19]